Nottingham, UK: Following a recent challenge in the US, early clinical drug development specialist Pharmaceutical Profiles (Nottingham, UK), has successfully defended its IP on the company’s core Enterion™ technology. The United States Patent and Trademark Office has re-examined Pharmaceutical Profiles’ claims and confirmed the validity of the principle Enterion patent. In addition, with the acceptance of a continuation patent application for the US, the company has further strengthened its position.
